Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Abdul-Ghani

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Drug Design, Development and Therapy|March 15, 2014
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patientsMustafa Cakirca, Cumali Karatoprak, Mehmet Zorlu, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 7, 2018
Reduced skeletal muscle phosphocreatine concentration in type 2 diabetic patients: a quantitative image-based phosphorus-31 MR spectroscopy studyErika M Ripley, Geoffrey D Clarke, Vala Hamidi, et al.
Diabetes|January 10, 2020
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 InhibitorsMariam Alatrach, Nitchakarn Laichuthai, Robert Martinez, et al.
Biomedicines|July 29, 2025
Investigating the Role of GDF-15 in Diabetes and Obesity: A Comprehensive Analysis of a Cohort from the KDEP StudyJehad Abubaker, Mohamed Abu-Farha, Ahmed N Albatineh, et al.
International Journal of Molecular Sciences|September 13, 2025
Circulating ORM2 as a Biomarker of Metabolic Dysfunction: Evidence from the KADEM Study in Kuwaiti AdultsMohamed Abu-Farha, Ahmed N Albatineh, Bader Alawadh, et al.
Diabetes Care|August 30, 2017
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With DiabetesGeoffrey D Clarke, Carolina Solis-Herrera, Marjorie Molina-Wilkins, et al.
Diabetes, Obesity & Metabolism|October 7, 2022
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetesAlexander J Moody, Marjorie Molina-Wilkins, Geoffrey D Clarke, et al.
Diabetes|July 16, 2025
Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate: A Randomized TrialSiham Abdelgani, Ahmed Khattab, John M Adams, et al.
Frontiers in Endocrinology|August 25, 2025
Association of wrist circumference with metabolic dysfunction associated fatty liver disease in the KADEM cohortFahad Al-Ajmi, Mohamed Abu-Farha, Ahmed N Albatineh, et al.
International Journal of Molecular Sciences|December 10, 2021
Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic DiseasesAl-Anood Al-Shamasi, Rozina Elkaffash, Meram Mohamed, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Drug Design, Development and Therapy|March 15, 2014
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patientsMustafa Cakirca, Cumali Karatoprak, Mehmet Zorlu, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 7, 2018
Reduced skeletal muscle phosphocreatine concentration in type 2 diabetic patients: a quantitative image-based phosphorus-31 MR spectroscopy studyErika M Ripley, Geoffrey D Clarke, Vala Hamidi, et al.
Diabetes|January 10, 2020
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 InhibitorsMariam Alatrach, Nitchakarn Laichuthai, Robert Martinez, et al.
Biomedicines|July 29, 2025
Investigating the Role of GDF-15 in Diabetes and Obesity: A Comprehensive Analysis of a Cohort from the KDEP StudyJehad Abubaker, Mohamed Abu-Farha, Ahmed N Albatineh, et al.
International Journal of Molecular Sciences|September 13, 2025
Circulating ORM2 as a Biomarker of Metabolic Dysfunction: Evidence from the KADEM Study in Kuwaiti AdultsMohamed Abu-Farha, Ahmed N Albatineh, Bader Alawadh, et al.
Diabetes Care|August 30, 2017
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With DiabetesGeoffrey D Clarke, Carolina Solis-Herrera, Marjorie Molina-Wilkins, et al.
Diabetes, Obesity & Metabolism|October 7, 2022
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetesAlexander J Moody, Marjorie Molina-Wilkins, Geoffrey D Clarke, et al.
Diabetes|July 16, 2025
Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate: A Randomized TrialSiham Abdelgani, Ahmed Khattab, John M Adams, et al.
Frontiers in Endocrinology|August 25, 2025
Association of wrist circumference with metabolic dysfunction associated fatty liver disease in the KADEM cohortFahad Al-Ajmi, Mohamed Abu-Farha, Ahmed N Albatineh, et al.
International Journal of Molecular Sciences|December 10, 2021
Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic DiseasesAl-Anood Al-Shamasi, Rozina Elkaffash, Meram Mohamed, et al.
Pageof 10